1. Home
  2. SLN vs RC Comparison

SLN vs RC Comparison

Compare SLN & RC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$7.13

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Logo Ready Capital Corproation

RC

Ready Capital Corproation

HOLD

Current Price

$1.72

Market Cap

257.3M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
RC
Founded
1994
2007
Country
United Kingdom
United States
Employees
116
442
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
236.2M
257.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLN
RC
Price
$7.13
$1.72
Analyst Decision
Buy
Hold
Analyst Count
5
4
Target Price
$42.60
$2.81
AVG Volume (30 Days)
303.7K
1.6M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
2.16%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$67.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.19
$1.50
52 Week High
$8.40
$4.75

Technical Indicators

Market Signals
Indicator
SLN
RC
Relative Strength Index (RSI) 51.08 44.23
Support Level $5.91 $1.56
Resistance Level $7.21 $2.12
Average True Range (ATR) 0.47 0.11
MACD -0.11 -0.03
Stochastic Oscillator 34.77 12.26

Price Performance

Historical Comparison
SLN
RC

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About RC Ready Capital Corproation

Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.

Share on Social Networks: